Qihan Biotechnology scores $67m

Qihan Biotechnology Co, a Chinese provider of genome editing technology to cell therapies and organ transplantation, has raised $67 million in financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this